CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 23rd Annual Needham Virtual Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Presentation Details
- Thursday, April 11th, at 11:45 a.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in virtual one-on-one meetings on Thursday, April 11th
A webcast of the panel can also be accessed under "Events & Presentations" in the Investors section of Foghorn's website, www.foghorntx.com, and will be available for ...